OncLiveUpfront Use of Immunotherapy for NCSLCOncLivePanelists: Mark A. Socinski, MD, Florida Hospital Cancer Institute; Tracey L. Evans, MD, University of Pennsylvania; Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center; Vali A. Papadimitrako… Continue reading
OncLiveLess Common Side Effects With Immunotherapy in MelanomaOncLiveInsights From: Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center; Claire Crowley, RN, Memorial Sloan Kettering Cancer Center; Michael B. Atkins, MD, Georgetown Lombardi Co… Continue reading
Agricultural Biotechnology: Emerging Technologies and Global MarketsYahoo FinanceBiotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and syntheti… Continue reading
|
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
StreetInsider.com Chardan Capital Markets initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $23.50. Analyst Madhu Kumar commented, “We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating … Crispr Therapeutics AG – Receive News & Ratings DailyBBNS Analysts Set $27.00 Target Price for Crispr Therapeutics AG (CRSP)Sports Perspectives Stock Analysts Favoring These Names: CRISPR Therapeutics AG (:CRSP) USD Partners LP (NYSE:USDP)Sherwood Daily The Cerbat Gem all 6 news articles » |
|
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
StreetInsider.com Analyst Madhu Kumar commented, “We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating (PT $23.50), on our view of possible upside on clinical leadership in CRISPR therapy overriding the risk of possible downside on the … |
|
ImMAGE Biotherapeutics’ DNA immunotherapy shows high efficacy with low toxicology results
PR Newswire (press release) BETHESDA, Md., March 27, 2017 /PRNewswire-USNewswire/ — ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that its immunotherapy successfully passed early toxicology and efficacy studies. |